Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Isthmin-1 (ISM1), a novel adipokine that reflects abdominal adipose tissue distribution in individuals with obesity

  • Lopez-Yus, Marta
  • Casamayor, Carmen
  • Soriano-Godes, Juan Jose
  • Borlan, Sofia
  • Gonzalez-Irazabal, Yolanda
  • Garcia-Sobreviela, Maria Pilar
  • Garcia-Rodriguez, Beatriz
  • del Moral-Bergos, Raquel
  • Calmarza, Pilar
  • Artigas, Jose Maria
  • Lorente-Cebrian, Silvia
  • Bernal-Monterde, Vanesa
  • Sanz-Paris, Alejandro
  • Arbones-Mainar, Jose M.
Background: The assessment of obesity-related health risks has traditionally relied on the Body Mass Index and waist circumference, but their limitations have propelled the need for a more comprehensive approach. The differentiation between visceral (VIS) and subcutaneous (SC) fat provides a finer-grained understanding of these risks, yet practical assessment methods are lacking. We hypothesized that combining the SC-VIS fat ratio with non-invasive biomarkers could create a valuable tool for obesity-related risk assessment. Methods and results: A clinical study of 125 individuals with obesity revealed significant differences in abdominal fat distribution measured by CT-scan among genders and distinct models of obesity, including visceral, subcutaneous, and the SC/VIS ratio. Stratification based on these models highlighted various metabolic changes. The SC/VIS ratio emerged as an excellent metric to differentiate metabolic status. Gene expression analysis identified candidate biomarkers, with ISM1 showing promise. Subsequent validation demonstrated a correlation between ISM1 levels in SC and plasma, reinforcing its potential as a non-invasive biomarker for fat distribution. Serum adipokine levels also correlated with the SC/VIS ratio. The Receiver Operating Characteristic analysis revealed ISM1’s efficacy in discriminating individuals with favorable metabolic profiles based on adipose tissue distribution. Correlation analysis also suggested that ISM1 was involved in glucose regulation pathways. Conclusion: The study’s results support the hypothesis that the SC-VIS fat ratio and its derived non-invasive biomarkers can comprehensively assess obesity-related health risks. ISM1 could predict abdominal fat partitioning and be a potential biomarker for evaluating obesity-related health risks.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-mediated deletion of adipocyte genes associated with NAFLD alters adipocyte lipid handling and reduces steatosis in hepatocytes in vitro

  • Lopez-Yus, Marta
  • Frendo-Cumbo, Scott
  • del Moral-Bergos, Raquel
  • Garcia-Sobreviela, Maria Pilar
  • Bernal-Monterde, Vanesa
  • Rydén, Mikael
  • Lorente-Cebrian, Silvia
  • Arbones-Mainar, Jose M.
Obesity is a major risk factor for the development of nonalcoholic fatty liver disease (NAFLD), and the subcutaneous white adi-pose tissue (scWAT) is the primary lipid storage depot and regulates lipidfluxes to other organs. Our previous work identifiedgenes upregulated in scWAT of patients with NAFLD:SOCS3,DUSP1,andSIK1. Herein, we knocked down (KD) their expres-sion in human adipose-derived mesenchymal stem cells (hADMSCs) using clustered regularly interspaced short palindromicrepeats (CRISPR)/Cas9 technology and characterized their phenotype. We found thatSOCS3,DUSP1,andSIK1expression inhADMSC-derived adipocytes was not critical for adipogenesis. However, the metabolic characterization of the cells suggestedthat the genes played important roles in lipid metabolism. Reduction ofSIK1expression significantly increased both de novolipogenesis (DNL) and palmitate-induced lipogenesis (PIL). Editing outSOCS3reduced DNL while increasing isoproterenol-induced lipolysis and insulin-induced palmitate accumulation. Conversely,DUSP1reduced PIL and DNL. Moreover, RNA-sequencing analysis of edited cells showed that these genes not only altered lipid metabolism but also other biological path-ways related to inflammatory processes, in the case ofDUSP1, extracellular matrix remodeling forSOCS3, or cellular transportforSIK1. Finally, to evaluate a possible adipocyte-hepatocyte axis, human hepatoma HepG2 cells were cocultured with editedhADMSCs-derived adipocytes in the presence of [3H]-palmitate. All HepG2 cells cultured with DUSP1-, SIK1-, or SOCS3-KD adi-pocytes decreased [3H]-palmitate accumulation compared with control adipocytes. These results support our hypotheses thatSOCS3,DUSP1,andSIK1regulate multiple aspects of adipocyte function, which may play a role in the progression of obesity-associated comorbidities, such as NAFLD.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Exploring functional products and early-life dynamics of gut microbiota

  • Martínez-Martínez, Ana B.
  • Lambán-Per, Belén M.
  • Lezaun, María
  • Rezusta, Antonio
  • Arbones-Mainar, José M.
Research on the microbiome has progressed from identifying specific microbial communities to exploring how these organisms produce and modify metabolites that impact a wide range of health conditions, including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. This review provides an overview of the bacteria commonly found in the intestinal tract, focusing on their main functional outputs. We explore biomarkers that not only indicate a well-balanced microbiota but also potential dysbiosis, which could foreshadow susceptibility to future health conditions. Additionally, it discusses the establishment of the microbiota during the early years of life, examining factors such as gestational age at birth, type of delivery, antibiotic intake, and genetic and environmental influences. Through a comprehensive analysis of current research, this article aims to enhance our understanding of the microbiota’s foundational development and its long-term implications for health and disease management.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery

  • Herrera-Marcos, Luis V.
  • Arbones-Mainar, Jose M.
  • Osada, Jesús
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease characterized by the build-up of fat in the liver of individuals in the absence of alcohol consumption. This condition has become a burden in modern societies aggravated by the lack of appropriate predictive biomarkers (other than liver biopsy). To better understand this disease and to find appropriate biomarkers, a new technology has emerged in the last two decades with the ability to explore the unmapped role of lipids in this disease: lipidomics. This technology, based on the combination of chromatography and mass spectrometry, has been extensively used to explore the lipid metabolism of NAFLD. In this review, we aim to summarize the knowledge gained through lipidomics assays exploring tissues, plasma, and lipoproteins from individuals with NAFLD. Our goal is to identify common features and active pathways that could facilitate the finding of a reliable biomarker from this field. The most frequent observation was a variable decrease (1–9%) in polyunsaturated fatty acids in phospholipids and non-esterified fatty acids in NAFLD patients, both in plasma and liver. Additionally, a reduction in phosphatidylcholines is a common feature in the liver. Due to the scarcity of studies, further research is needed to properly detect lipoprotein, plasma, and tissue lipid signatures of NAFLD etiologies, and NAFLD subtypes, and to define the relevance of this technology in disease management strategies in the push toward personalized medicine.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study

  • Espina, Silvia
  • Casas-Deza, Diego
  • Bernal-Monterde, Vanesa
  • Royo-Esteban, Ana
  • García-Sobreviela, Maria Pilar
  • Calmarza, Pilar
  • Martinez-Martinez, Ana B.
  • Osada, Jesús
  • Arbones-Mainar, Jose M.
Background: There are conflicting studies reporting both an increase and a decrease in vitamin B12 (VB12) levels in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to dissect the effects of steatosis and fibrosis on VB12. Methods: This is a cross-sectional study including all patients with a vibration-controlled transient elastography (VCTE) performed at the Hospital Miguel Servet (Zaragoza, Spain) between 2019 and 2022 for a chronic liver disease and having a recent blood test for VB12 levels. Liver fibrosis was assessed by VCTE and hepatic steatosis by ultrasonography and/or through controlled attenuation parameter (CAP). Results: 1195 patients (NAFLD n = 441, other chronic liver disease n = 754) were included. Median age was 57 years, 53% female. Patients with NAFLD had lower levels of VB12 compared to the rest of chronic liver diseases (289 vs. 313 pg/mL, p < 0.001). A significant negative correlation was observed between VB12 levels and hepatic steatosis measured by CAP (r = −0.13, p < 0.001). A significant positive correlation was observed between VB12 levels and liver stiffness in patients with NAFLD in both sexes (men r = 0.31, p < 0.001 and women r = 0.15, p = 0.016). A significant association between VB12 levels and liver fibrosis in cirrhosis stage was observed in patients with NAFLD (OR 1.06, 95% CI, 1.025–1.098, p = 0.001). Conclusion: VB12 levels were lower with greater hepatic steatosis. In NAFLD, VB12 levels were lower compared to other chronic liver diseases but their levels increased with higher liver stiffness and in cirrhosis stage.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Phenolic compounds and epigenetic mechanisms regulating gene expression: effects on human health

  • Lorente-Cebrián, Silvia
  • Costa, André G. V.
  • Castillo-Rivas, J. Andrés
  • Castro, Marta
  • Arbonés-Mainar, José Miguel
  • Goñi, Saioa
  • Remón, Sara
  • Aranaz, Paula
  • López, Víctor
  • Martín-Burriel, Inmaculada
  • Milagro, Fermín I.
Abstract Phenolic compounds are a large class of phytochemicals with relevant physiological effects that are naturally found in plant-origin foods and derived products. Beneficial effects associated with polyphenol consumption are related to their ability to prevent and/or counteract disease features: they exert anti-inflammatory, antioxidant and anticancer effects, as well as protective actions against metabolic diseases. Phenolic compounds and their metabolites can modulate cell function by regulating gene expression. These effects are partially mediated through specific changes in epigenetic mechanisms such as DNA methylation, histone modifications and microRNA (miRNA) expression. Some polyphenols affect DNA methylation and are effective in counteracting deleterious actions induced by inflammatory/pro-oxidant factors, both in in vitro and in vivo settings. Specific mechanisms include modulation of methyl-transferases, whose levels are inhibited upon polyphenols treatment. Some polyphenols are histone deacetylase inhibitors, which prevent transcriptional repression and suppress tumor and inflammation genes by affecting selective regulation of miRNA expression. Their mostly recognized actions as anti-inflammatory and antioxidants seem to be partially mediated through regulation of individual miRNAs. Due to these actions, polyphenols and polyphenol-derived metabolites are under study in clinical and interventional trials for their benefits on inflammation and/or metabolic disorders. In conclusion, phenolic compounds might be an interesting approach to contribute to human homeostasis given their capacity to dynamically regulate epigenetic factors at cellular and systemic level. The present review aims to study available evidence regarding regulatory effects of polyphenols on gene expression, specifically mediated through epigenetic mechanisms.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

MASLD-Related Hepatocarcinoma: Special Features and Challenges

  • Yagüe-Caballero, Carmen
  • Casas-Deza, Diego
  • Pascual-Oliver, Andrea
  • Espina-Cadena, Silvia
  • Arbones-Mainar, Jose M.
  • Bernal-Monterde, Vanesa
Metabolic-associated steatohepatitis liver disease (MASLD) currently impacts a quarter of the global population, and its incidence is expected to increase in the future. As a result, hepatocellular carcinoma associated with MASLD is also on the rise. Notably, this carcinoma does not always develop alongside liver cirrhosis, often leading to a more advanced stage at diagnosis. The challenge lies in accurately identifying patients who are at a higher risk to tailor screening processes effectively. Additionally, several therapeutic approaches are being explored to prevent hepatocellular carcinoma, although there are no universally accepted guidelines yet.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications

  • Casas-Deza, Diego
  • García-López, Santiago
  • Bernal-Monterde, Vanesa
  • Polo-Cuadro, Cristina
  • Yagüe-Caballero, Carmen
  • Arbones-Mainar, José M.
Obesity and inflammatory bowel disease (IBD) are two chronic conditions whose prevalence continues to rise globally. Emerging evidence suggests a bidirectional interplay between them, mediated by shared pathophysiological pathways. This narrative review explores the mechanisms Ilinking obesity to IBD development and progression, focusing on the role of adipose tissue dysfunction. Both diseases exhibit intestinal dysbiosis, low-grade systemic inflammation, and impaired epithelial barrier integrity, contributing to immune activation. Visceral adiposity, particularly mesenteric fat, acts as an immunometabolic organ producing cytokines and adipokines that may exacerbate intestinal inflammation. In Crohn’s disease, mesenteric fat expansion, or “creeping fat”, is associated with transmural inflammation, fibrosis, and luminal narrowing. Epidemiological data on obesity as a risk factor for IBD remain inconsistent due to methodological heterogeneity and confounders. Similarly, the impact of obesity on IBD outcomes, including disease activity, phenotype, and the need for surgery, is debated. While mesenteric surgical approaches like Kono-S anastomosis showed initial promise in reducing recurrence, recent randomized trials offer conflicting results. Finally, metabolic drugs such as statins, metformin, and GLP-1 receptor agonists have demonstrated anti-inflammatory properties with potential utility in IBD management. Prospective studies are warranted to elucidate the clinical significance of obesity and metabolic dysfunction in IBD and evaluate targeted therapeutic strategies.